ORIC Pharmaceuticals, Inc. (ORIC)

6,74 -0,41 (-5,73%) Al cierre: 04:00PM EDT

ORIC Pharmaceuticals, Inc.

240 East Grand Avenue
2nd Floor
South San Francisco, CA 94080
United States
650 388 5600
https://www.oricpharma.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 102

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Richard A. Heyman Ph.D.	Co-Founder, Independent Chairman & Member of Scientific Advisory Board	93k	N/A	1957
Dr. Jacob M. Chacko M.B.A., M.D.	President, CEO & Director	961k	N/A	1979
Mr. Dominic G. Piscitelli CPA, M.B.A.	Chief Financial Officer	654,74k	N/A	1975
Dr. Pratik S. Multani M.D., M.S.	Chief Medical Officer	715,22k	N/A	1967
Dr. Charles L. Sawyers B.A., M.D., Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1959
Dr. Scott W. Lowe Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Dr. Lori Sickels Friedman Ph.D.	Chief Scientific Officer	N/A	N/A	1964
Dr. Christian V. Kuhlen Esq., J.D., M.D.	General Counsel	N/A	N/A	1973
Mr. Daniel Iazzetti	VP & Head of People	N/A	N/A	N/A
Dr. Edna Chow Maneval	Senior Vice President of Clinical Development	N/A	N/A	1960

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Gobierno corporativo

El ISS Governance QualityScore de ORIC Pharmaceuticals, Inc., a día 1 de junio de 2024, es 8. Las puntuaciones base son Auditoría: 10; Tablero: 5; Derechos de los accionistas: 8; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.